Dose intensity in patients with metastatic breast cancer - Time for novel thoughts?

被引：7

作者：

Bergh, J

机构：

来源：

ANNALS OF ONCOLOGY | 1997年 / 8卷 / 02期

关键词：

D O I：

10.1023/A:1008227103230

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：109 / 110

页数：2

相关论文

共 9 条

[1] Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group [J].

Bastholt, L ;

Dalmark, M ;

Gjedde, SB ;

Pfeiffer, P ;

Pedersen, D ;

Sandberg, E ;

Kjaer, M ;

Mouridsen, HT ;

Rose, C ;

Nielsen, OS ;

Jakobsen, P ;

Bentzen, SM .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1146-1155

[2] INFLUENCE OF TREATMENT SCHEDULE ON TOXICITY AND EFFICACY OF CYCLOPHOSPHAMIDE, EPIRUBICIN, AND FLUOROURACIL IN METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL COMPARING WEEKLY AND EVERY-4-WEEK ADMINISTRATION [J].

BLOMQVIST, C ;

ELOMAA, I ;

RISSANEN, P ;

HIETANEN, P ;

NEVASAARI, K ;

HELLE, L .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :467-473

[3] Doubling epirubicin dose intensity (100 mg/m(2) versus 50 mg/m(2)) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer [J].

Brufman, G ;

Colajori, E ;

Ghilezan, N ;

Lassus, M ;

Martoni, A ;

Perevodchikova, N ;

Tosello, C ;

Viaro, D ;

Zielinski, C ;

Krainer, M ;

Salzer, H ;

Schuller, J ;

Dittrich, C ;

Scheithauer, W ;

Zamagni, C ;

Ambrosini, G ;

Colucci, G ;

Gentilini, P ;

Zaniboni, A ;

Pacini, P ;

Bianco, R ;

Mustacchi, G ;

DAprile, M ;

DeMatteis, A ;

Oliveira, C ;

Jordaan, J ;

Gudgeon, A ;

VanZyl, J ;

Rakowsky, E ;

Inbar, M ;

Rath, P ;

Cohen, Y ;

Shani, A ;

Fried, G ;

Hegg, R ;

Neto, AB ;

Bader, G ;

Braga, RF ;

Vitoc, C ;

Puerto, VML ;

Valle, AE ;

Salazar, JD ;

Sanchez, JC ;

Villela, GM ;

Fountzilas, G .

ANNALS OF ONCOLOGY, 1997, 8 (02) :155-162

[4] A COMPARISON OF 2 DOSES OF ADRIAMYCIN IN THE PRIMARY CHEMOTHERAPY OF DISSEMINATED BREAST-CARCINOMA [J].

CARMOPEREIRA, J ;

COSTA, FO ;

HENRIQUES, E ;

GODINHO, F ;

CANTINHOLOPES, MG ;

SALESLUIS, A ;

RUBENS, RD .

BRITISH JOURNAL OF CANCER, 1987, 56 (04) :471-473

[5] DECREASED EFFICACY OF CYCLOPHOSPHAMIDE, EPIRUBICIN AND 5-FLUOROURACIL IN METASTATIC BREAST-CANCER WHEN REDUCING TREATMENT DURATION FROM 18 TO 6 MONTHS [J].

EJLERTSEN, B ;

PFEIFFER, P ;

PEDERSEN, D ;

MOURIDSEN, HT ;

ROSE, C ;

OVERGAARD, M ;

SANDBERG, E ;

KRISTENSEN, B .

EUROPEAN JOURNAL OF CANCER, 1993, 29A (04) :527-531

[6] DOSE-RESPONSE RELATIONSHIP OF EPIRUBICIN-BASED 1ST-LINE CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A PROSPECTIVE RANDOMIZED TRIAL [J].

FOCAN, C ;

ANDRIEN, JM ;

CLOSON, MT ;

DICATO, M ;

DRIESSCHAERT, P ;

FOCANHENRARD, D ;

LEMAIRE, M ;

LOBELLE, JP ;

LONGREE, L ;

RIES, F .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1253-1263

[7] Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative [J].

Gurney, H .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) :2590-2611

[8] EPIRUBICIN AT 2 DOSE LEVELS WITH PREDNISOLONE AS TREATMENT FOR ADVANCED BREAST-CANCER - THE RESULTS OF A RANDOMIZED TRIAL [J].

HABESHAW, T ;

PAUL, J ;

JONES, R ;

STALLARD, S ;

STEWART, M ;

KAYE, SB ;

SOUKOP, M ;

SYMONDS, RP ;

REED, NS ;

RANKIN, EM .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) :295-304

[9] Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients [J].

Sandstrom, M ;

Freijs, A ;

Larsson, R ;

Nygren, P ;

Fjallskog, ML ;

Bergh, J ;

Karlsson, MO .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1581-1588